S233-119

Reported

Restoring Confidence in the World Anti-Doping Agency Act of 2025

119th Congress Introduced Jan 23, 2025

Summary

What This Bill Does

The bill updates the Office of National Drug Control Policy statute for WADA oversight. It modernizes references to the United States Olympic and Paralympic Committee, defines independent athletes, and directs ONDCP, in consultation with the United States Anti-Doping Agency, USOPC, and the Team USA Athletes' Commission, to use available tools to press WADA on governance independence, conflict-of-interest safeguards, athlete representation, and accountability.

Who Benefits and How

United States Olympic athletes benefit from stronger federal pressure for fair anti-doping governance and independent athlete representation at WADA. United States Paralympic athletes benefit because the bill explicitly updates the statute to include the United States Olympic and Paralympic Committee. Independent athletes benefit because the bill defines them and centers their representation in WADA decision-making roles. The United States Anti-Doping Agency benefits from a clearer consultation role with ONDCP on WADA governance and reform pressure. Congressional oversight committees benefit from annual determinations and accountability information about WADA conduct.

Who Bears the Burden and How

The Office of National Drug Control Policy must make annual WADA-related determinations and coordinate with USADA, USOPC, and athlete representatives. The World Anti-Doping Agency faces U.S. pressure to implement governance reforms, conflict-of-interest policies, and athlete-representation changes. WADA Executive Committee and Foundation Board members face scrutiny over independence, conflicts of interest, and representation. International sports federations may face pressure when WADA governance issues affect U.S. participation and confidence.

Key Provisions

  • Modernizes statutory references from the United States Olympic Committee to the United States Olympic and Paralympic Committee.
  • Defines independent athletes for WADA governance purposes.
  • Requires ONDCP consultation with USADA, USOPC, and the Team USA Athletes' Commission on WADA matters.
  • Directs federal pressure for credible WADA governance, conflict-of-interest reforms, and athlete representation.
  • Requires recurring determinations about whether WADA has met governance and accountability standards.

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

Expands the Office of National Drug Control Policy's duties toward the World Anti-Doping Agency by requiring annual determinations and reform pressure focused on independent athlete representation, governance reforms, conflicts of interest, and fair treatment of United States athletes.

Key Policy Areas

Sports, Government Oversight

Primary Purpose

Expands the Office of National Drug Control Policy's duties toward the World Anti-Doping Agency by requiring annual determinations and reform pressure focused on independent athlete representation, governance reforms, conflicts of interest, and fair treatment of United States athletes.

Policy Domains

Sports Government Oversight

Bill provisions

Identified Gains
  • United States Olympic athletes
  • United States Paralympic athletes
  • Independent athletes
  • United States Anti-Doping Agency
  • Congressional oversight committees
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: rs
Independent athletes: ,
United States Olympic athletes: ,
United States Anti-Doping Agency: ,
United States Paralympic athletes: ,
Congressional oversight committees: ,
Identified Costs
  • Office of National Drug Control Policy
  • World Anti-Doping Agency
  • WADA Executive Committee
  • WADA Foundation Board
  • International sports federations
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: rs
WADA Foundation Board: ,
WADA Executive Committee: ,
World Anti-Doping Agency: ,
International sports federations: ,
Office of National Drug Control Policy: ,

Legislative Progress

Reported
Introduced Committee Passed
Feb 23, 2026

Placed on Senate Legislative Calendar under General Orders. Calendar No. …

Feb 23, 2026

Committee on Commerce, Science, and Transportation. Reported by Senator Cruz …

Jun 25, 2025

Committee on Commerce, Science, and Transportation. Ordered to be reported …

Feb 23, 2025

Reported by Mr. Cruz, with an amendment

Jan 23, 2025

Read twice and referred to the Committee on Commerce, Science, …

Jan 23, 2025

Mrs. Blackburn (for herself, Mr. Van Hollen, Mrs. Capito, Mr. …

Jan 23, 2025

Introduced in Senate

Jan 23, 2025

Mrs. Blackburn (for herself, Mr. Van Hollen, Mrs. Capito, Mr. …

Stakeholder Effects

cui bono?

How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.

Sports & Recreation
12 mentions across 3 clauses
+9 positive -3 negative

United States Anti-Doping Agency, United States Olympic athletes, United States Paralympic athletes

Positive-direction: United States Anti-Doping Agency, United States Olympic athletes, United States Paralympic athletes

Negative-direction: World Anti-Doping Agency

Government
3 mentions across 3 clauses
-3 negative

Office of National Drug Control Policy

3/4
sections analyzed
Full impact breakdown

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Sports Government Oversight
Actor Mappings
"wada"
→ World Anti-Doping Agency
"ondcp"
→ Office of National Drug Control Policy

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology